[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity
KalVista Pharmaceuticals (KALV) insider activity: Christopher Yea, the company芒鈧劉s Chief Development Officer and a director, received 3,125 restricted stock units (RSUs) that convert one-for-one into common shares upon settlement. The RSUs were reported as acquired upon vesting and increase the reporting person's contingent claim on 3,125 shares. To satisfy tax withholding when those RSUs settled, the reporting person sold 1,954 shares at $13.42 per share in a "sell-to-cover" transaction, which was not a discretionary sale. After these transactions the reporting person beneficially owned 132,052 common shares and continued to hold RSUs representing 34,375 underlying shares that vest quarterly at one-sixteenth of the total per quarter while service continues.
Attivit脿 interna di KalVista Pharmaceuticals (KALV): Christopher Yea, Chief Development Officer e membro del consiglio, ha ricevuto 3.125 unit脿 azionarie vincolate (RSU) convertibili in azioni ordinarie uno a uno al momento della liquidazione. Le RSU sono state segnalate come acquisite al momento del vesting e aumentano il diritto contingente del dichiarante su 3.125 azioni. Per coprire le imposte dovute alla liquidazione di tali RSU, il dichiarante ha venduto in un'operazione "sell-to-cover" 1.954 azioni a $13,42 ciascuna; tale vendita non 猫 stata discrezionale. Dopo queste operazioni il dichiarante deteneva beneficiariamente 132.052 azioni ordinarie e continuava a possedere RSU corrispondenti a 34.375 azioni sottostanti, che maturano trimestralmente in porzioni pari a un sedicesimo del totale per trimestre fino al termine del servizio.
Actividad interna de KalVista Pharmaceuticals (KALV): Christopher Yea, Director de Desarrollo y miembro del consejo, recibi贸 3.125 unidades restringidas de acciones (RSU) que se convierten una a una en acciones ordinarias al liquidarse. Las RSU se informaron como adquiridas al consolidarse y aumentan la reclamaci贸n contingente del informante sobre 3.125 acciones. Para cubrir la retenci贸n fiscal al liquidarse dichas RSU, el informante vendi贸 en una operaci贸n "sell-to-cover" 1.954 acciones a $13,42 por acci贸n, venta que no fue discrecional. Tras estas operaciones, el informante pose铆a beneficiariamente 132.052 acciones ordinarias y segu铆a teniendo RSU que representan 34.375 acciones subyacentes, las cuales vencen trimestralmente en fracciones de una dieciseisava parte del total por trimestre mientras contin煤e el servicio.
KalVista Pharmaceuticals (KALV) 雮措秬鞛� 瓯半灅: 斓滉碃臧滊皽毂呾瀯鞛�(CDO)鞚挫瀽 鞚挫偓鞚� Christopher Yea電� 3,125臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃溂氅�, 鞚措姅 鞝曥偘 鞁� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 頃措嫻 RSU電� 氩犾姢韺� 鞁� 旆摑鞙茧 氤搓碃霅橃棃瓿� 氤搓碃鞛愳潣 3,125欤�鞐� 雽�頃� 鞛犾灛鞝� 甓岆Μ毳� 歃濌皜鞁滌及鞀惦媹雼�. 鞚� RSU 鞝曥偘鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤搓碃鞛愲姅 牍勳瀯鞚橃爜 瓯半灅鞚� "sell-to-cover" 氚╈嫕鞙茧 1,954欤茧ゼ 欤茧嫻 $13.42鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃鞛愲姅 132,052欤�鞚� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頄堨溂氅�, 瓿勳啀 攴茧頃橂姅 霃欖晥 攵勱赴氤勲 齑濎暋鞚� 1/16鞌� 氩犾姢韸鸽悩電� 34,375欤检潣 旮办磮欤检嫕鞐� 靸侅潙頃橂姅 RSU毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Op茅rations d'initi茅s chez KalVista Pharmaceuticals (KALV) : Christopher Yea, directeur du d茅veloppement et administrateur, a re莽u 3 125 unit茅s d'actions restreintes (RSU) convertibles en actions ordinaires 脿 raison d'une pour une lors du r猫glement. Les RSU ont 茅t茅 d茅clar茅es comme acquises au vesting et augmentent la cr茅ance conditionnelle de la personne d茅clarante sur 3 125 actions. Pour couvrir la retenue fiscale li茅e au r猫glement de ces RSU, la personne d茅clarante a vendu dans une op茅ration 芦 sell-to-cover 禄 1 954 actions 脿 13,42 $ chacune, vente qui n'茅tait pas discr茅tionnaire. Apr猫s ces op茅rations, la personne d茅tenait b茅n茅ficiairement 132 052 actions ordinaires et continuait de d茅tenir des RSU repr茅sentant 34 375 actions sous-jacentes, qui acqui猫rent droit trimestriellement 脿 hauteur d'un seizi猫me du total par trimestre tant que le service se poursuit.
Insider-Aktivit盲ten bei KalVista Pharmaceuticals (KALV): Christopher Yea, Chief Development Officer und Direktor, erhielt 3.125 Restricted Stock Units (RSUs), die bei Aus眉bung eins zu eins in Stammaktien umgewandelt werden. Die RSUs wurden bei Vesting als erworben gemeldet und erh枚hen den bedingten Anspruch der meldenden Person auf 3.125 Aktien. Zur Begleichung der Steuerabz眉ge beim Settlement dieser RSUs verkaufte die meldende Person in einer nicht diskretion盲ren "Sell-to-Cover"-Transaktion 1.954 Aktien zu je $13,42. Nach diesen Transaktionen hielt die meldende Person wirtschaftlich 132.052 Stammaktien und behielt weiterhin RSUs im Umfang von 34.375 zugrundeliegenden Aktien, die quartalsweise in jeweils einem Sechzehntel des Gesamtbetrags vesten, solange die Dienstzeit andauert.
- Officer received 3,125 RSUs demonstrating continued compensation alignment with company performance
- RSUs convert one-for-one to common stock, preserving the executive芒鈧劉s economic interest in the company
- Vesting schedule is defined (1/16th quarterly), providing predictable future equity alignment
- Sell-to-cover of 1,954 shares reduced the number of shares added to the reporting person's direct holdings
- Some vested units remain subject to service-based vesting which could lapse if service terminates
Insights
TL;DR: Officer received routine RSU vesting and used a standard sell-to-cover to meet tax obligations; this is a common, non-discretionary insider event.
The filing shows a standard equity compensation settlement by a senior executive. The 3,125 RSUs reflect compensation realization rather than a market-timed purchase. The subsequent sale of 1,954 shares to cover taxes is explicitly non-discretionary per the filing. Remaining direct beneficial ownership of 132,052 shares and outstanding RSUs for 34,375 shares indicate continued alignment with shareholders through equity compensation. No unusual trading pattern or material change in control is evident from this Form 4.
TL;DR: The transaction is compensatory and routine; it modestly increases vested equity while a sell-to-cover reduces net shares delivered.
This Form 4 records vesting of RSUs that convert to common stock on a one-for-one basis and a contemporaneous sell-to-cover of 1,954 shares at $13.42 to satisfy tax withholding. The vesting schedule disclosed (quarterly 1/16th) means future small, periodic vesting events will occur if service continues. From an investor-materiality perspective, the trades are small relative to typical public-company free float and are disclosed consistently with Section 16 obligations.
Attivit脿 interna di KalVista Pharmaceuticals (KALV): Christopher Yea, Chief Development Officer e membro del consiglio, ha ricevuto 3.125 unit脿 azionarie vincolate (RSU) convertibili in azioni ordinarie uno a uno al momento della liquidazione. Le RSU sono state segnalate come acquisite al momento del vesting e aumentano il diritto contingente del dichiarante su 3.125 azioni. Per coprire le imposte dovute alla liquidazione di tali RSU, il dichiarante ha venduto in un'operazione "sell-to-cover" 1.954 azioni a $13,42 ciascuna; tale vendita non 猫 stata discrezionale. Dopo queste operazioni il dichiarante deteneva beneficiariamente 132.052 azioni ordinarie e continuava a possedere RSU corrispondenti a 34.375 azioni sottostanti, che maturano trimestralmente in porzioni pari a un sedicesimo del totale per trimestre fino al termine del servizio.
Actividad interna de KalVista Pharmaceuticals (KALV): Christopher Yea, Director de Desarrollo y miembro del consejo, recibi贸 3.125 unidades restringidas de acciones (RSU) que se convierten una a una en acciones ordinarias al liquidarse. Las RSU se informaron como adquiridas al consolidarse y aumentan la reclamaci贸n contingente del informante sobre 3.125 acciones. Para cubrir la retenci贸n fiscal al liquidarse dichas RSU, el informante vendi贸 en una operaci贸n "sell-to-cover" 1.954 acciones a $13,42 por acci贸n, venta que no fue discrecional. Tras estas operaciones, el informante pose铆a beneficiariamente 132.052 acciones ordinarias y segu铆a teniendo RSU que representan 34.375 acciones subyacentes, las cuales vencen trimestralmente en fracciones de una dieciseisava parte del total por trimestre mientras contin煤e el servicio.
KalVista Pharmaceuticals (KALV) 雮措秬鞛� 瓯半灅: 斓滉碃臧滊皽毂呾瀯鞛�(CDO)鞚挫瀽 鞚挫偓鞚� Christopher Yea電� 3,125臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃溂氅�, 鞚措姅 鞝曥偘 鞁� 1雽�1 牍勳湪搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 頃措嫻 RSU電� 氩犾姢韺� 鞁� 旆摑鞙茧 氤搓碃霅橃棃瓿� 氤搓碃鞛愳潣 3,125欤�鞐� 雽�頃� 鞛犾灛鞝� 甓岆Μ毳� 歃濌皜鞁滌及鞀惦媹雼�. 鞚� RSU 鞝曥偘鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤搓碃鞛愲姅 牍勳瀯鞚橃爜 瓯半灅鞚� "sell-to-cover" 氚╈嫕鞙茧 1,954欤茧ゼ 欤茧嫻 $13.42鞐� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃鞛愲姅 132,052欤�鞚� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頄堨溂氅�, 瓿勳啀 攴茧頃橂姅 霃欖晥 攵勱赴氤勲 齑濎暋鞚� 1/16鞌� 氩犾姢韸鸽悩電� 34,375欤检潣 旮办磮欤检嫕鞐� 靸侅潙頃橂姅 RSU毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Op茅rations d'initi茅s chez KalVista Pharmaceuticals (KALV) : Christopher Yea, directeur du d茅veloppement et administrateur, a re莽u 3 125 unit茅s d'actions restreintes (RSU) convertibles en actions ordinaires 脿 raison d'une pour une lors du r猫glement. Les RSU ont 茅t茅 d茅clar茅es comme acquises au vesting et augmentent la cr茅ance conditionnelle de la personne d茅clarante sur 3 125 actions. Pour couvrir la retenue fiscale li茅e au r猫glement de ces RSU, la personne d茅clarante a vendu dans une op茅ration 芦 sell-to-cover 禄 1 954 actions 脿 13,42 $ chacune, vente qui n'茅tait pas discr茅tionnaire. Apr猫s ces op茅rations, la personne d茅tenait b茅n茅ficiairement 132 052 actions ordinaires et continuait de d茅tenir des RSU repr茅sentant 34 375 actions sous-jacentes, qui acqui猫rent droit trimestriellement 脿 hauteur d'un seizi猫me du total par trimestre tant que le service se poursuit.
Insider-Aktivit盲ten bei KalVista Pharmaceuticals (KALV): Christopher Yea, Chief Development Officer und Direktor, erhielt 3.125 Restricted Stock Units (RSUs), die bei Aus眉bung eins zu eins in Stammaktien umgewandelt werden. Die RSUs wurden bei Vesting als erworben gemeldet und erh枚hen den bedingten Anspruch der meldenden Person auf 3.125 Aktien. Zur Begleichung der Steuerabz眉ge beim Settlement dieser RSUs verkaufte die meldende Person in einer nicht diskretion盲ren "Sell-to-Cover"-Transaktion 1.954 Aktien zu je $13,42. Nach diesen Transaktionen hielt die meldende Person wirtschaftlich 132.052 Stammaktien und behielt weiterhin RSUs im Umfang von 34.375 zugrundeliegenden Aktien, die quartalsweise in jeweils einem Sechzehntel des Gesamtbetrags vesten, solange die Dienstzeit andauert.
FAQ
What did KALV insider Christopher Yea report on Form 4?
How many KALV shares does Christopher Yea beneficially own after these transactions?
How many unvested RSUs remain for Christopher Yea and how do they vest?
Was the sale of KALV shares a discretionary transaction?
At what price were the KALV shares sold in the sell-to-cover?
